Gastroenterology
Cohort Study | Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis
24 Jan, 2023 | 14:14h | UTC
Cohort Study | Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy in 120 000 repeated screening colonoscopies
23 Jan, 2023 | 13:36h | UTCCommentaries:
Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay
Commentary on Twitter
Large registry-based study finds strong potential for risk-adapted #colorectalcancer screening, suggests extension of screening endoscopy intervals beyond 10 years may be warranted particularly in asymptomatic female and younger participants. https://t.co/fChg6DRyPw @DKFZ
— JAMA Internal Medicine (@JAMAInternalMed) January 17, 2023
M-A | Dietary interventions for the treatment of inflammatory bowel diseases
20 Jan, 2023 | 14:30h | UTC
Commentary on Twitter
@berkeleydoc @nehagastrord Nice systematic rv & meta-analysis! https://t.co/24wFZvRgcx
Good reminder how strength of evidence 1) lags behind clinical practice recommendations, 2) is still needed to support those recommendations… #IBD #diet #crohnsdisease pic.twitter.com/EmI94F6xif
— KT Park (@KTPARKMD) December 10, 2022
Under a Creative Commons (CC BY-NC-ND 4.0) License
Cross-sectional study | Non-heavy alcohol use associated with liver fibrosis and ‘nonalcoholic’ steatohepatitis
20 Jan, 2023 | 14:29h | UTCNon-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)
Commentary: Study finds non-heavy alcohol use associated with liver fibrosis – Boston University School of Medicine
ACC Guidelines Update | Diagnosis and management of celiac disease
18 Jan, 2023 | 14:40h | UTCCommentaries:
ACG Updates Clinical Guidance on Diagnosing Celiac Disease – HCP Live
ACG Clinical Guideline | Diagnosis and management of gastrointestinal subepithelial lesions
18 Jan, 2023 | 14:39h | UTC
Cohort Study | Proton pump inhibitors are unlikely to be major teratogens during pregnancy
18 Jan, 2023 | 14:14h | UTC
Commentary on Twitter
This large nationwide cohort study of 2.7 million pregnancies suggested that maternal proton pump inhibitor use during pregnancy is not associated with an increased risk of congenital malformations. https://t.co/fvgthhIYa7
— JAMA Network Open (@JAMANetworkOpen) January 10, 2023
RCT | Reduced adenoma miss rate with 9-minute vs. 6-minute withdrawal times for screening colonoscopy
18 Jan, 2023 | 14:13h | UTCCommentary: Longer withdrawal time reduces miss rates in screening colonoscopy – MDedge
Commentary on Twitter
📕 #RapidRCTinAJG, accelerating the time from RCT to publication
Reduced Adenoma Miss Rate With 9-Minute vs 6-Minute Withdrawal Times for Screening Colonoscopy: A Multicenter Randomized Tandem Trial by Zhao, et al.
👉 https://t.co/SSIktB0Aoc@JasmohanBajaj @MLongMD #RedJournal pic.twitter.com/OwJhzeKYPA
— AJG – The American Journal of Gastroenterology (@AmJGastro) January 5, 2023
AGA clinical practice update on diagnosis and management of acute hepatic porphyrias
17 Jan, 2023 | 13:19h | UTC
RCT | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy
17 Jan, 2023 | 13:10h | UTCInvited commentary: Treatment withdrawal in Crohn’s disease: slowly becoming clearer – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary on Twitter
New research – Louis et al – Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialhttps://t.co/T40BmgHtem#IBD #GITwitter #medtwitter pic.twitter.com/iOIbi0WowU
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 12, 2023
Review | Liver intensive care for the general intensivist
17 Jan, 2023 | 12:59h | UTCLiver intensive care for the general intensivist – Anaesthesia
Development and validation of a prognostic nomogram for older patients with acute-on-chronic liver diseases
15 Jan, 2023 | 19:46h | UTCSee also: dynamic nomogram
Cohort Study | Antibiotic exposure linked to increased risk of inflammatory bowel disease
13 Jan, 2023 | 13:25h | UTCNews Release: Frequent use of antibiotics may heighten inflammatory bowel disease risk in over 40s – BMJ Newsroom
Commentaries:
Antibiotics may increase risk of inflammatory bowel disease, study finds – CIDRAP
Antibiotic Exposure Positively Linked to IBD Development – HealthDay
Commentary on Twitter
#GUTPressRelease on the paper by @AdamFayeMD, @KristineAllin, @manasiagrawalmd, @PREDICTIBD et al
"Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study" viahttps://t.co/zc9bG3CpSm#GUTInTheNews pic.twitter.com/xra8wfEgnr
— Gut Journal (@Gut_BMJ) January 9, 2023
Review | The pathogenesis and therapeutic strategies of heat stroke-induced liver injury
13 Jan, 2023 | 13:07h | UTCThe pathogenesis and therapeutic strategies of heat stroke-induced liver injury – Critical Care
RCT | Second-line levofloxacin-based quadruple therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication
12 Jan, 2023 | 13:06h | UTCSecond-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Liou et al – Second-line levofloxacin-based quadruple therapy vs bismuth-based quadruple therapy for H pylori eradication and long-term changes to the gut #microbiota and antibiotic resistome: an RCThttps://t.co/Aipu3TRyFr#Hpylori #microbiome #AMR @emadelomar pic.twitter.com/aeFMAI3FCj
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 20, 2022
M-A | Blood endotoxin levels as biomarker of non-alcoholic fatty liver disease
12 Jan, 2023 | 12:57h | UTC
Review | Early diagnosis and prevention of infections in cirrhosis
12 Jan, 2023 | 12:47h | UTCEarly Diagnosis and Prevention of Infections in Cirrhosis – Seminars in Liver Disease
RCT | Dupilumab in adults and adolescents with eosinophilic esophagitis
11 Jan, 2023 | 14:27h | UTCDupilumab in Adults and Adolescents with Eosinophilic Esophagitis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Weekly Dupilumab Beneficial in Eosinophilic Esophagitis – HealthDay
M-A | Dietary interventions for the treatment of inflammatory bowel diseases
11 Jan, 2023 | 13:54h | UTC
RCT | The addition of Olanzapine to a triple antiemetic regimen effectively prevents nausea and vomiting during highly emetogenic chemotherapy.
16 Dec, 2022 | 13:32h | UTCRelated:
Phase 1b/2a Study | Safety, pharmacokinetics, and pharmacodynamics of Pegozafermin in patients with non-alcoholic steatohepatitis.
16 Dec, 2022 | 13:29h | UTCSafety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Loomba et al – Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a study https://t.co/49u1OQKSRJ#livertwitter #NASH #fattyliver @DrLoomba pic.twitter.com/2emqc8Qkfw
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 13, 2022
Polled analysis of RCTs | Linaclotide reduced response time for irritable bowel syndrome with constipation symptoms.
16 Dec, 2022 | 13:17h | UTC
RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.
16 Dec, 2022 | 13:15h | UTC
A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements.
16 Dec, 2022 | 13:09h | UTC
SR | Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
14 Dec, 2022 | 14:51h | UTCTreatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins – Cochrane Library